NNNtokozo Ndlovu

Ntokozo Ndlovu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ntokozo Ndlovu has a total of 125 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Albumin–Bilirubin Grade and HIV Status in Hepatocellular Carcinoma as Predictors of Survival in Zimbabwe

    by Tinashe A. Mazhindu, Vincent Nyangwara, Michalina A. Montaño, Edith Matsikidze, Onesai Chihaka, Charley Jang, Margaret Z. Borok, Collen Masimirembwa, Ntokozo Ndlovu

    Background: Infection with HIV increases the risk of developing hepatocellular carcinoma, and the albumin–bilirubin grade assesses liver function and has been shown to be prognostic. We evaluated the albumin–bilirubin score/grade and the HIV status of hepatocellular carcinoma patients in Zimbabwe and explored the impact on median survival. Methods: A 10-year retrospective observational study of hepatocellular carcinoma patients was conducted at a single tertiary-level cancer center in Harare, Zimbabwe. Survival probabilities were estimated using the Kaplan–Meier method, and differences between groups were compared using the log-rank test and Cox proportional hazards regression. Results: A total of 95 participants were evaluated, of whom 72.6% were male. Most HCC cases were diagnosed using imaging and serum alpha-fetoprotein, with 59% presenting at Barcelona Clinic Liver Cancer stage C or D. Compared with patients who were HIV-negative, patients who were HIV-positive (OR 2.2; 95% CI 1.54–5.26, p = 0.0008) or had an unknown HIV status (OR 4.2; 95% CI 2.2–8; p < 0.0001) had higher odds of being at ALBI grade 3 at the time of HCC diagnosis. ALBI grade 1 patients had better median survival compared to grade 2 and 3 patients, though this result was statistically insignificant (grade 2: HR = 1.45, 95% CI: 0.30–7.13; grade 3: HR = 1.47, 95% CI: 0.28–7.60). Regarding HIV status, median survival was 2.4 months for HIV-positive patients and 2.6 months for HIV-negative patients (p = 0.51); HIV positivity was not significantly associated with median survival (HR = 1.50, 95% CI: 0.46–4.91). Only 30.5% of patients received cancer therapy, all of which was palliative, with no observed survival benefit. Conclusions: The majority of hepatocellular carcinoma patients in Zimbabwe were diagnosed at an advanced stage, with hepatitis B or C viral infections and alcohol consumption identified as primary risk factors. Median survival rates were low. Neither HIV infection nor ALBI score grading had a significant impact on median survival.

  • Trends in the Incidence of Cancers of the GI Tract in Harare, Zimbabwe, 1990-2019

    by Eric Chokunonga, Margaret Borok, Leolin Katsidzira, Zvavahera Mike Chirenje, Rudo Makunike-Mutasa, Ntokozo Ndlovu, Justice Mudavanhu, Biying Liu, D. Maxwell Parkin

    PURPOSE: Data on long-term time trends in the incidence of cancer are an invaluable resource for tracking the evolution of the disease in populations, but they are very scarce in Africa. The Zimbabwe National Cancer Registry of Harare can report on the evolution of the cancer epidemic over a 30-year period. METHODS: Trends in age-standardized incidence rates in the Black (African) population (males and females) are reported for six cancers of the GI tract (oral cavity plus oropharynx, esophagus, stomach, colon plus rectum, liver, and pancreas). RESULTS: There has been a steady increase in the incidence of colorectal cancer, at about 2.5% annually, in both sexes, whereas liver cancer has declined, rather more rapidly in males (3.6% annually) than in females (3% annually). Although the incidence is much lower, cancers of the oral cavity and oropharynx have increased in both sexes (3.5% annually in males, 2.8% [nonsignificant] in females). The incidence of stomach cancer has risen over the period, although significantly so only in the most recent decade (2010-2019), before which there had been a slight decline in rates. While esophageal cancer has declined in incidence in men (1.8% annually), it has increased in women (2.4% annually), with adenocarcinomas comprising an increasing proportion (although still less common than squamous cell carcinomas). There has been no significant trend in the incidence of pancreatic cancer. CONCLUSION: While some of these trends are related to population-level changes in lifestyles and exposure to environmental factors (such as hepatitis viruses and aflatoxins), the reasons for other changes in incidence are more obscure. While some may be in part due to improvements in diagnostic techniques (endoscopy and imaging), others merit further investigation.

  • Pharmacogenomic Impact on Breast Cancer Survival for Black Zimbabwean Patients on Tamoxifen

    by Tinashe A. Mazhindu, E. Duke Chase, Matthew Joel, Ntokozo Ndlovu, Margaret Z. Borok, Collen Masimirembwa, Audrey E. Hendricks, on behalf of Consortium for Genomics and Therapeutics in Africa (CGTA)

    PURPOSE: About one in three Black Africans carry the African-predominant allele variants CYP2D6*17 and/or CYP2D6*29, which confer a reduced enzymatic activity. CYP2D6 intermediate metabolizers (IM) have a reduced biotransformation rate of tamoxifen compared with its more active metabolite endoxifen. METHODS: A prospective cohort study of Black Zimbabwean patients with hormone receptor–positive breast cancer on tamoxifen therapy was conducted. Patients were genotyped for CYP2D6 and followed up for event-free survival (EFS) on tamoxifen. RESULTS: In total, 18 CYP2D6 IM and 33 normal metabolizers (NM) were enrolled. At 2 years, the estimated EFS was 40.1% (95% CI, 20.3 to 79.4) for the IM group and 84.0% (95% CI, 72.1 to 97.9) for the NM group (log-rank P = .0021). A Cox proportional hazards model, after adjusting for BMI, stage at diagnosis, and previous breast cancer surgery, estimated about a 5.5-fold higher hazard of recurrence, progression, or death in IM compared with NM. CONCLUSION: Individuals with hormone receptor–positive breast cancer who are CYP2D6 NM had better disease recurrence and progression-free survival outcomes compared with IM.


  • Open Access

    Trends in the incidence of cancers related to HIV-AIDS in Harare, Zimbabwe 1990-2019

    by Eric Chokunonga, Rudo Makunike-Mutasa, Margaret Borok, Mike Z Chirenje, Ntokozo Ndlovu, Justice Mudavanhu, Apollo Tsitsi, Biying Liu, Donald Maxwell Parkin

    Background: HIV prevalence in Harare reached a maximum of around 33% of adults in 1995, before falling to 12% in 2019. We examine trends in the incidence of Kaposi sarcoma (KS), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, and squamous cell conjunctival cancers (SCCCs) in the population of Harare in relation to changes in HIV prevalence, and the increasing availability and use of antiretroviral therapy (ART). Methods: Data from the population-based cancer registry of Harare are used to calculate incidence rates for the Black (African) population for the years 1990-2019. Results: Incidence of KS increased to a peak in the late 1990s, after which rates declined, especially at younger ages. Mean age at diagnosis increased by about 8 years in men and 6 years in women. SCCC shows a similar trend to that of KS, with a dramatic 10-fold increase in incidence, followed by an equivalent fall. Although Hodgkin lymphoma showed no change in incidence over the 30-year period, rates of NHL progressively increased. Incidence in younger adults (aged younger than 44) stabilized after about 2001 but continued to increase in older individuals. Conclusions: The availability of high-quality cancer registry data over a long period has provided a unique opportunity to study the effects of the epidemic of HIV-AIDs and of ART availability on the risk of cancer in an African population. As HIV prevalence fell and ART coverage expanded, incidence of KS and SCCC declined, whereas for NHL the trends suggest that long-term infection with HIV may pose an increased risk, despite ART.


  • Open Access

    Healthcare provider perspectives on integrating HIV care into cancer centers in Malawi, South Africa, Uganda, and Zimbabwe

    by Michalina A Montaño, Alfred Jatho, Cecilia Nassolo, Noleb Mugisha, Agatha Bula, Maganizo B Chagomerana, Margaret Borok, Takudzwa J Mtisi, Maureen Joffe, Rachel A. Bender Ignacio, et al.


  • Open Access

    Review of: "On The Need For Better Inform Results From Randomized Clinical Trials In Oncology"

    by Ntokozo Ndlovu

    This is an article that draws interest to the interpretation of RCTs from a patient management point of view. The authors highlight the importance of reporting HR as well as AR and RR to enhance patient management decisions. Clinical decision-making...

  • Open Access

    Pulmonary Tuberculosis: A Comorbidity or Misdiagnosis of Primary Lung Cancer in Africa?

    by Tinashe Adrian Mazhindu, Ntokozo Ndlovu, Edith Matsikidze, Shirley Chibonda, Webster Kadzatsa

    Background: Globally, over 2 million new cases of lung cancer are diagnosed annually, representing about 11% of all cancers


  • Open Access

    Africa Guidelines for Hepatocellular Carcinoma Buildup Process

    by Ghassan K. Abou-Alfa, Mary Afihene, Marinela Capanu, Yuelin Li, Joanne F. Chou, Akwi Asombang, Olusegun Isaac Alatise, Adda Bounedjar, Lina Cunha, Hailemichael Desalegn Mekonnen, et al.

    PURPOSE: Hepatocellular carcinoma (HCC), the fourth most common cancer in Africa, has a dismal overall survival of only 3 months like in sub-Saharan Africa. This is affected by the low gross domestic product and human development index, absence of coherent guidelines, and other factors.METHODS: An open forum for HCC-experienced health care workers from Africa and the rest of the world was held in October 2021. Participants completed a survey to help assess the real-life access to screening, diagnoses, and treatment in the North and Southern Africa (NS), East and West Africa (EW), Central Africa (C), and the rest of the world.RESULTS: Of 461 participants from all relevant subspecialties, 372 were from Africa. Most African participants provided hepatitis B vaccination and treatment for hepatitis B and C. More than half of the participants use serum alpha-fetoprotein and ultrasound for surveillance. Only 20% reported using image-guided diagnostic liver biopsy. The Barcelona Clinic Liver Cancer is the most used staging system (52%). Liver transplant is available for only 28% of NS and 3% EW. C reported a significantly lower availability of resection. Availability of local therapy ranged from 94% in NS to 62% in C. Sorafenib is the most commonly used systemic therapy (66%). Only 12.9% reported access to other medications including immune checkpoint inhibitors. Besides 42% access to regorafenib in NS, second-line treatments were not provided.CONCLUSION: Similarities and differences in the care for patients with HCC in Africa are reported. This reconfirms the major gaps in access and availability especially in C and marginally less so in EW. This is a call for concerted multidisciplinary efforts to achieve and sustain a reduction in incidence and mortality from HCC in Africa.


  • Open Access

    Pharmacogenetics and Adverse Events in the Use of Fluoropyrimidine in a Cohort of Cancer Patients on Standard of Care Treatment in Zimbabwe

    by Boluwatife Lawrence Afolabi, Tinashe Mazhindu, Chikwambi Zedias, Margaret Borok, Ntokozo Ndlovu, Collen Masimirembwa, on behalf of Consortium for Genomics and Therapeutics in Africa (CGTA)

    Fluoropyrimidines are commonly used in the treatment of colorectal cancer. They are, however, associated with adverse events (AEs), of which gastrointestinal, myelosuppression and palmar-plantar erythrodysesthesia are the most common. Clinical guidelines are used for fluoropyrimidine dosing based on dihydropyrimidine dehydrogenase (DPYD) genetic polymorphism and have been shown to reduce these AEs in patients of European ancestry. This study aimed to evaluate, for the first time, the clinical applicability of these guidelines in a cohort of cancer patients on fluoropyrimidine standard of care treatment in Zimbabwe. DNA was extracted from whole blood and used for DPYD genotyping. Adverse events were monitored for six months using the Common Terminology Criteria for AEs (CTCAE) v.5.0. None of the 150 genotyped patients was a carrier of any of the pathogenic variants (DPYD*2A, DPYD*13, rs67376798, or rs75017182). However, severe AEs were high (36%) compared to those reported in the literature from other populations. There was a statistically significant association between BSA (p = 0.0074) and BMI (p = 0.0001) with severe global AEs. This study has shown the absence of the currently known actionable DPYD variants in the Zimbabwean cancer patient cohort. Therefore, the current pathogenic variants in the guidelines might not be feasible for all populations hence the call for modification of the current DPYD guidelines to include minority populations for the benefit of all diverse patients.


  • Open Access

    Competency-Based Workforce Development and Education in Global Oncology

    by Nazik Hammad, Ntokozo Ndlovu, Laura Mae Carson, Doreen Ramogola-Masire, Indranil Mallick, Scott Berry, E. Oluwabunmi Olapade-Olaopa

    The healthcare workforce plays a pivotal role in cancer care delivery, leadership, policy, education, and research in complex cancer systems. To ensure quality and relevance, health professionals must have the necessary competencies to deliver patient-centered and efficient care, coupled with the ability to work in teams and manage health resources wisely. This paper aims to review the concept of competency-based medical education (CBME) in the context of oncology to provide insights and guidance for those interested in adopting or adapting competency-based education in training programs. The results of a scoping review of CBME in oncology are presented here to describe the current status of CBME in oncology. The literature describing the implementation and evaluation of CBME in oncology training programs for medical professionals internationally is summarized and key themes identified to provide practical guidance for educators. Further, the paper identifies critical competencies for oncology education and training globally and presents recommendations and opportunities for collaboration in competency-based education and training in oncology. The authors argue for increased global collaboration and networking in the realm of CBME to facilitate the establishment of a competent global cancer care workforce.